-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Squamous cells are the main cells of the skin structure.
the United States, more than 1 million people are diagnosed with squamous cell carcinoma each year and 2,500 die from the disease.
squamous cell carcinoma (the second most common skin cancer, after substrate cell carcinoma) generally occurs in the area of daylight exposure, people with more sunlight have a higher risk of squamous cell skin cancer, white people are susceptible to the disease.
, a biopharmaceutical company focused on RNAi drugs, announced today that its leading candidate drug, STP705, has achieved positive results in its Phase IIa clinical study of squamous cell skin cancer.
the trial consisted of five dose incremental trial groups, ranging from 10 to 120 μg, with a total of 25 patients in each group.
participants received STP705 injections once a week for up to six weeks.
the main endpoint of the trial is to assess the histological clearance rate of tumor cells within the lesions.
showed that 76% (19/25) of all patients achieved complete histological removal.
90% lesions histological removal was achieved in the two optimal dosage ranges.
no significant adverse events associated with treatment were reported in the study, nor were there serious adverse events.
。
